Showing results (51-60 of 382) with videos related to
Sort By:
Pageof 39
Urologic Oncology|March 16, 2015
National estimated costs of never events following radical prostatectomyChristopher M Deibert, Max Kates, James M McKiernan, et al.Urologic Oncology|June 13, 2012
The effect of race and gender on the surgical management of the small renal massMax Kates, Michael J Whalen, Gina M Badalato, et al.Urology|February 5, 2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future researchJulie N Graff, Charles G Drake, Tomasz M BeerDiscovery Medicine|May 28, 2016
Recent advances in immunotherapy for kidney cancerMark W Ball, Mohamad E Allaf, Charles G DrakeBJU International|March 5, 2014
Balancing cardiovascular (CV) and cancer death among patients with small renal masses: modification by CV riskHiten D Patel, Max Kates, Phillip M Pierorazio, et al.Cancer Research|April 22, 2014
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancerW Nathaniel Brennen, Charles G Drake, John T IsaacsCancer Immunology Research|December 7, 2014
PD-1 blockade in renal cell carcinoma: to equilibrium and beyondLauren C Harshman, Charles G Drake, Toni K ChoueiriCurrent Opinion in Immunology|January 13, 2012
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunitySuzanne L Topalian, Charles G Drake, Drew M PardollCancer Cell|April 11, 2015
Immune checkpoint blockade: a common denominator approach to cancer therapySuzanne L Topalian, Charles G Drake, Drew M PardollClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I RiniPageof 39